SPSang-Gon Park

Sang-Gon Park

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sang-Gon Park has a total of 78 co-authors. Here are the top co-authors by number of shared publications:

  • Hong-Beum Kim

    Department of Premedical Course, Chosun University School of Medicine, Gwangju, Republic of Korea

    14 shared publications
  • Hee-Jeong Lee

    Department of Internal Medicine, Hemato-oncology, Chosun University Hospital, Gwangju, Republic of Korea

    13 shared publications
  • Seong-Hun Kim

    Department of Internal Medicine, Hemato-oncology, Chosun University Hospital, Gwangju, Republic of Korea

    5 shared publications
  • Hong Beum Kim

    DNA Damage Response Network Center, Chosun University School of Medicine, Gwangju, Republic of Korea

    4 shared publications
  • Hyun-Jong Lim

    Department of Medicine, Graduate School of Chosun University, Gwangju, Republic of Korea

    4 shared publications
  • Jung-Hee Lee

    Laboratory of Genomic Instability and Cancer Therapeutics, Cancer Mutation Research Center, Chosun University School of Medicine, Gwangju, Republic of Korea

    4 shared publications

Latest Publications

  • Open Access

    NPM1 Drives ERK1/2-dependent Tumor Progression in Lung Cancer

    by Hong-Beum Kim, Hee-Jeong Lee, Sang-Gon Park

    Lung cancer is the most lethal malignancy worldwide, and there remains an urgent need for reliable biomarkers to improve diagnosis and treatment. Nucleophosmin 1 (NPM1), a nucleolar phosphoprotein, has been implicated in hematological cancers, but its significance in lung cancer is less clear. This study investigated the oncogenic role of NPM1 in lung cancer and its involvement in ERK1/2 pathway activation in lung cancer cells. Transcriptomic data from TCGA were analyzed to assess NPM1 expression in lung cancer and normal tissues. In vitro assays using A549 and H1299 cells were conducted following siRNA-mediated silencing of NPM1. Cell proliferation, soft agar colony formation, and western blot analyses were performed. In vivo tumorigenicity was tested using a nude mouse xenograft model. NPM1 expression was significantly elevated in lung cancer tissues compared with normal samples. Silencing NPM1 reduced proliferation, colony formation, and tumor growth. Mechanistic studies revealed that NPM1 knockdown decreased phosphorylation of ERK1/2, indicating its role in activating this pathway. NPM1 contributes to lung cancer progression via ERK1/2 signaling. These results highlight NPM1 as a novel oncogene and suggest its potential as a diagnostic and prognostic biomarker in lung cancer.

  • POM121 Drives Gastric Cancer Progression via the mTOR/p70S6K Signaling Axis

    by Hong-Beum Kim, Seong-Hun Kim, Hye-Hwa Lee, Hee-Jeong Lee, Sang-Gon Park

    Background/Aim: Gastric cancer (GC) remains one of the leading causes of cancer-related mortality worldwide. This study aimed to clarify the oncogenic function of POM121 and its involvement in signaling pathways driving tumor progression. Materials and Methods: POM121 expression was analyzed in six GC cell lines and one normal gastric epithelial cell line, as well as in clinical datasets. Functional consequences of POM121 knockdown were assessed in AGS and KATO-III cells using cell proliferation, migration, soft agar colony formation, proteomic profiling, and in vivo xenograft models. Phosphorylation of p70S6 kinase at Thr389 and Thr421/Ser424 was examined to determine downstream signaling. Results: POM121 was consistently found to be upregulated in GC tissues and cell lines. Silencing of POM121 significantly inhibited proliferation, migration, anchorage-independent growth, and tumorigenicity in vivo. Proteomic analysis revealed that suppression of POM121 attenuated phosphorylation of p70S6K at Thr389 and Thr421/Ser424, indicating impaired mTOR-p70S6K signaling. Conclusion: POM121 promotes GC progression by enhancing proliferative and invasive phenotypes through p70S6 kinase-mediated signaling. These findings establish POM121 as a novel oncogene, prognostic biomarker, and potential therapeutic target in GC.

  • Oncogenic Role and Clinical Significance of NPM1 in Colorectal Cancer via the AKT/mTOR Signaling Pathway

    by Hong-Beum Kim, Hee-Jeong Lee, Sang-Gon Park

    Background/Aim: Colorectal cancer (CRC) remains a major global health challenge with poor survival in advanced disease. Identifying new oncogenic drivers is essential for improving diagnosis and therapy. This study investigated the oncogenic role of nucleophosmin 1 (NPM1) in CRC and its involvement in the AKT/mTOR signaling pathway. Materials and Methods: TCGA-COAD datasets were analyzed to compare NPM1 expression in tumor and normal tissues. Functional assays (MTT proliferation, soft agar colony formation, migration, and in vivo xenograft models) were performed after siRNA-mediated NPM1 knockdown in HCT-116 and DLD-1 cells. Western blotting and phospho-kinase arrays were used to evaluate phosphorylation of AKT, mTOR, and p70 S6 kinase. Results: NPM1 expression was significantly upregulated in CRC tissues. Knockdown of NPM1 suppressed proliferation, migration, anchorage-independent growth, and in vivo tumorigenicity. Mechanistically, NPM1 depletion reduced phosphorylation of AKT, mTOR, and p70 S6 kinase, while total protein levels were unchanged. Downstream oncogenic regulators, including MYC and AP-1 components (c-Jun and c-FOS), were also decreased. Conclusion: NPM1 acts as an oncogenic driver in colorectal cancer by activating the AKT/mTOR signaling pathway. Elevated NPM1 expression highlights its potential as a diagnostic, prognostic, and therapeutic biomarker in CRC.

  • Open Access

    Capillary Hemangioma of the Breast Parenchyma Mimicking New Primary Cancer or Metastasis During Ramucirumab Therapy for Advanced Gastric Cancer

    by Hong-Beum Kim, Yeon-Ah Lee, Seong-Hun Kim, Sang-Gon Park

    Background/Aim: Ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor-2 (VEGFR-2), has been shown to prolong survival in patients with advanced gastric cancer when combined with paclitaxel as second-line chemotherapy in the RAINBOW study. The most common adverse events include hypertension, proteinuria, and hemorrhage, reflecting its anti-angiogenic activity. Although the VEGF signaling pathway is strongly implicated in the pathogenesis of hemangiomas, the development of new hemangiomas during VEGFR-2 inhibition is rarely reported. Case Report: A 38-year-old woman with stage IV gastric adenocarcinoma presented with peritoneal dissemination and lymph node metastasis. She initially received FOLFOX plus immune checkpoint inhibitor therapy, achieving a partial response before disease progression. Second-line treatment with paclitaxel and ramucirumab was initiated. During therapy, chest computed tomography revealed a newly developed contrast-enhancing nodule in the left breast parenchyma, raising suspicion of metastasis or primary breast carcinoma. Breast ultrasonography confirmed a hypervascular lesion, and ultrasound-guided biopsy demonstrated numerous capillary-sized vessels lined by bland endothelial cells, consistent with capillary hemangioma. Owing to deterioration of her general condition, chemotherapy was temporarily discontinued. Despite subsequent third-line FOLFIRI and fourth-line trifluridine/tipiracil treatment, the patient eventually died of disease progression. Notably, follow-up chest CT scans showed gradual reduction and eventual spontaneous disappearance of the breast hemangioma, independent of systemic therapy. Conclusion: This is a rare case of a breast parenchymal capillary hemangioma arising during ramucirumab therapy for advanced gastric cancer, which regressed spontaneously. Clinicians should recognize that atypical vascular lesions may develop paradoxically during VEGFR-2 blockade and confirm histological diagnosis to avoid misinterpretation as metastasis or new primary malignancy.

  • Adenylate Kinase 2 Promotes Tumor Progression in Small-cell Lung Cancer via PI3K/AKT/mTOR Signaling

    by Hong-Beum Kim, Yong Sub NA, Seong-Hun Kim, Hee-Jeong Lee, Sang-Gon Park

    Background/Aim: Small-cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic progress. Adenylate kinase 2 (AK2), a mitochondrial isoenzyme involved in nucleotide metabolism and apoptosis regulation, has been implicated in tumorigenesis, but its role in SCLC remains undefined. This study aimed to investigate the oncogenic function of AK2 in SCLC and its regulatory mechanism through the PI3K/AKT/mTOR signaling pathway. Materials and Methods: AK2 expression was analyzed using the GSE60052 dataset and validated using western blotting in SCLC cell lines. Functional assays, including MTT, proliferation, colony formation, and phospho-kinase array profiling, were performed following siRNA-mediated AK2 knockdown in HCC-33 and H417 cells. Western blotting was used to confirm pathway alterations. In vivo tumorigenicity was assessed in xenograft models. Results: AK2 was markedly up-regulated in SCLC tissues and cell lines. Silencing AK2 significantly inhibited proliferation and clonogenic growth of SCLC cells and reduced tumorigenicity in vivo. Phospho-kinase analysis and western blot validation demonstrated that AK2 knockdown altered phosphorylation of key components in the PI3K/AKT/mTOR pathway, including AKT and mTOR. Conclusion: AK2 acts as an oncogenic driver in SCLC, promoting tumor progression through PI3K/AKT/mTOR signaling. Targeting AK2 may represent a novel therapeutic strategy and predictive biomarker in SCLC management.


  • Open Access

    Antibody-Mediated Therapy in Gastric Cancer: Past, Present, and Future

    by Hong-Beum Kim, Sang-Gon Park

    The limited efficacy of cytotoxic chemotherapy in the context of gastric cancer treatment is largely driven by profound molecular and biological heterogeneity. In contrast, the development of antibody-mediated therapies has ushered in a new era of precision oncology by enabling selective molecular targeting and immune modulation. This review includes a comprehensive overview of the evolution of antibody-based therapeutics in gastric cancer, highlighting early breakthroughs, subsequent setbacks, and recent advances that have reshaped the treatment landscape. We summarize the current standard regimens targeting HER2, VEGFR2, PD-1/PD-L1, and CLDN18.2 and examine pivotal clinical trials evaluating monoclonal antibodies directed against these pathways. We also discuss emerging therapeutic modalities, including next-generation antibody–drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies. Trastuzumab first established HER2-targeted therapy in gastric cancer, but the failure of trastuzumab emtansine (T-DM1) led to a decade-long stagnation until the advent of trastuzumab deruxtecan (T-DXd), which demonstrated robust clinical activity and defined a new standard of care. While bevacizumab failed to improve survival, the anti-VEGFR2 antibody ramucirumab emerged as an effective second-line therapy. Immune checkpoint inhibitors, including nivolumab and pembrolizumab, have been incorporated into first-line treatment for PD-L1-positive disease based on landmark trials such as CheckMate 649 and KEYNOTE-811. More recently, the CLDN18.2-targeted antibody zolbetuximab has expanded therapeutic options for biomarker-selected patients. Concurrently, a diverse pipeline of immune-based strategies—such as TROP2-directed ADCs, bispecific antibodies, and CAR-T cell therapies—is undergoing active clinical development. Together, advances in biomarker-driven antibody therapeutics are accelerating personalized cancer care and improving clinical outcomes in patients with gastric cancer.


  • Open Access

    SLX1 Inhibition Enhances Olaparib Sensitivity by Impairing Homologous Recombination Repair in Breast Cancer

    by Jin-Young Kim, Jeeho Kim, In-Youb Chang, Sang-Gon Park, Ho Jin You, Young Jin Jeon, Jung-Hee Lee

    While PARP inhibitors like Olaparib are effective against BRCA1-deficient breast cancers, their efficacy in BRCA1-proficient tumors depends on the functional status of homologous recombination (HR) repair. Here, we identify the structure-specific endonuclease SLX1 as a key regulator of HR and a determinant of Olaparib sensitivity in BRCA1-intact breast cancer. SLX1 is frequently upregulated in breast cancer and associated with poor prognosis. Functional studies revealed that SLX1 promotes RAD51-mediated HR repair of DNA double-strand breaks. Consequently, SLX1 depletion reduces HR efficiency, increases chromosomal instability, and sensitizes breast-proficient breast cancer cells to DNA-damaging agents, including camptothecin, ionizing radiation, and Olaparib. In contrast, SLX1 overexpression enhances DNA repair capacity and promotes Olaparib resistance. In vivo, SLX1 knockdown synergizes with Olaparib to suppress tumor growth in xenograft models. These findings establish SLX1 as a critical regulator of HR function in BRCA1-proficient breast cancer and a promising target for restoring PARP inhibitor sensitivity through induced HR deficiency.

  • Down-regulation of ACSM3 Promotes Tumorigenesis in Breast Cancer

    by Hong-Beum Kim, Seong-Hun Kim, Hee-Jeong Lee, Sang-Gon Park

    Background/Aim: Breast cancer is one of the most frequently diagnosed cancers worldwide. This study aimed to investigate the biological function and clinical significance of acyl-CoA synthetase medium-chain family member 3 (ACSM3) in breast cancer. Materials and Methods: RNA-seq data analysis was performed to evaluate ACSM3 expression in breast cancer tissues compared with normal breast tissues. Functional studies, including migration and invasion assays in vitro, as well as orthotopic xenograft models in vivo, were conducted to assess the role of ACSM3 in breast cancer progression. Results: ACSM3 expression was significantly reduced in tumor tissues compared with normal breast tissues, with down-regulation observed in approximately 75% of cases. Over-expression of ACSM3 suppressed breast cancer cell migration and invasion and was associated with increased AKT phosphorylation. In xenograft models, ACSM3 over-expression inhibited tumor growth and metastatic potential. Conclusion: ACSM3 functions as a tumor suppressor in breast cancer by regulating the WNT/AKT signaling pathway, thereby inhibiting cell proliferation, migration, and invasion. These results suggest that ACSM3 may serve as a potential therapeutic target for breast cancer treatment.

  • Open Access

    Antibody-Mediated Therapy in Gastric Cancer: Past, Present, and Future

    by Hong-Beum Kim, Sang-Gon Park

    Gastric cancer has historically relied on cytotoxic chemotherapy, yet its considerable mo lecular heterogeneity has limited therapeutic efficacy. The development of anti-body-mediated therapies has marked a new era in precision oncology, enabling selective targeting of biomarkers such as HER2, VEGFR2, PD-1/PD-L1, and CLDN18.2. This review summarizes the evolution of antibody-based strategies in gastric cancer, beginning with trastuzumab, the first HER2-targeted treatment, followed by the decade-long stagnation after the failure of T-DM1, and the recent establishment of trastuzumab deruxtecan (T-DXd) as a new standard of care. We further examine advances in anti-angiogenic therapy with ramucirumab, the incorporation of immune checkpoint inhibitors such as nivolumab and pembrolizumab into first-line regimens, and the clinical validation of CLDN18.2, culmi-nating in the approval of zolbetuximab. Emerging modalities—including next-generation antibody–drug conjugates (ADCs), bispecific antibodies, TROP2-directed agents, and CLDN18.2-targeted CAR-T cells—are also discussed. Finally, key challenges such as treatment resistance, real-time biomarker monitoring, and optimal sequencing in mul-ti-biomarker–positive patients are explored. Collectively, antibody-mediated therapy con-tinues to shift gastric cancer management toward increasingly personalized and durable treatment strategies.

  • GNAO1: A Novel Tumor Suppressor Gene in Colorectal Cancer Pathogenesis

    by Hong-Beum Kim, Woo Young Choi, Seong-Hun Kim, Hee-Jeong Lee, Sang-Gon Park

    Background/Aim: This study examined the role of GNAO1 as a potential tumor suppressor gene in colorectal cancer (CRC). Materials and Methods: RNA-seq data analysis revealed a significant GNAO1 down-regulation in colon cancer tissues compared to normal colon tissues. Results: GNAO1 over-expression in CRC cell lines inhibited cell proliferation, migration, and tumor formation both in vitro and in vivo. This study suggests that GNAO1 exerts its tumor-suppressive effects by inhibiting the mTOR/S6K signaling pathway. The observed correlation between GNAO1 expression and cancer progression highlights its potential as a prognostic marker and therapeutic target in CRC. Conclusion: This study provides a foundation for further exploration of the molecular mechanisms by which GNAO1 influences CRC pathogenesis, with significant implications for its application in clinical settings.